This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
About novel targeted agents in HCC
Because progress in HCC therapeutics is extremely slow
This page is a summary of: Regorafenib: a newly approved drug for advanced hepatocellular carcinoma, Future Oncology, August 2017, Future Medicine,
DOI: 10.2217/fon-2017-0237.
You can read the full text:
The following have contributed to this page
International Journal of Women s Health
Syrian refugee women not only suffered the refuging journey but also faced the burden of being the heads of their households in a new community. We aimed to investigate the mental health status, tr...
Journal of Geriatric Oncology
This study describes for the first time the cancer burden among adults aged 65 years or older in Latin America and the Caribbean.
Cancer Science
A new mathematical model was established and validated to forecast and define sensitive targets in the kynurenine pathway (Kynp) in pancreatic cancer
